New dengue vaccine trial aims to overcome past failures
NCT ID NCT05691530
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial tested a new live-attenuated dengue vaccine in 127 healthy adults aged 18 to 59. The goal was to see how safe the vaccine is and how the immune system responds, especially in people who have had dengue before. Participants received one shot and were monitored for side effects and antibody levels over several months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rDEN3Δ30/31-7164 vaccine (a weakened live dengue virus)
- What this could lead to
- If successful, this could help develop a safer, more effective dengue vaccine that works for people with different levels of prior exposure.
- What could go wrong
- This is an early Phase 1 trial with only 127 participants, so results may not apply to larger populations. The vaccine may cause side effects or fail to produce strong immunity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPONSE TO DENGUE EXPOSURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States